Amryt Pharma PLC Result of AGM (1015F)
10 Juli 2019 - 12:23PM
UK Regulatory
TIDMAMYT
RNS Number : 1015F
Amryt Pharma PLC
10 July 2019
10 July 2019
AIM: AMYT
Euronext Growth: AYP
Amryt Pharma plc
("Amryt" or the "Company")
RESULTS OF AGM
Amryt, the biopharmaceutical company focused on rare and orphan
diseases, is pleased to announce that at its Annual General Meeting
held earlier today, all resolutions, including that to affect the
Capital Reorganisation, were duly passed.
The full text of each resolution was included in the notice of
the meeting, which was posted to shareholders on 12 June 2019, and
is available on the Company's website www.amrytpharma.com.
Application has been made to the London Stock Exchange for the
New Ordinary Shares to be admitted to trading on AIM and to
Euronext Dublin for the New Ordinary Shares to be admitted to
trading on the Euronext Growth Market ("Admission"). It is expected
that such Admission will become effective at 8.00 am on 11 July
2019.
Following Admission the Company's issued share capital will
consist of 45,802,881 New Ordinary Shares. The total number of
voting rights in the Company will therefore be 45,802,881 New
Ordinary Shares.
The ISIN for the New Ordinary Shares is GB00BKB1MS30.
Unless otherwise stated, defined terms in this announcement not
otherwise defined shall have the same meaning as is ascribed to
them in the announcement released on 12 June 2019.
Enquiries:
Amryt Pharma plc +353 (1) 518 0200
Joe Wiley, CEO
Rory Nealon, CFO/COO
Shore Capital +44 (0) 20 7408 4090
Financial Advisor, NOMAD and Joint
Broker
Edward Mansfield, Mark Percy, Daniel
Bush
Stifel +44 (0) 20 7710 7600
Joint Broker
Jonathan Senior, Ben Maddison
Davy +353 (1) 679 6363
Euronext Growth Advisor and Joint
Broker
John Frain, Daragh O'Reilly
Consilium Strategic Communications +44 (0) 20 3709 5700
Amber Fennell, Matthew Neal, David
Daley
About Amryt
Amryt is a biopharmaceutical company focused on developing and
delivering innovative new treatments to help improve the lives of
patients with rare or orphan diseases.
Lojuxta(R) is an approved treatment for adult patients with the
rare cholesterol disorder - Homozygous Familial
Hypercholesterolaemia ("HoFH"). This disorder impairs the body's
ability to remove low density lipoprotein ("LDL") cholesterol
("bad" cholesterol) from the blood, typically leading to abnormally
high blood LDL cholesterol levels in the body from before birth -
often ten times more than people without HoFH - and subsequent
aggressive and premature narrowing and blocking of blood vessels.
Lojuxta(R) is indicated as an adjunct to a low-fat diet and other
lipid-lowering medicinal products with or without LDL apheresis in
adult patients with HoFH.
Amryt is the marketing authorisation holder and has an exclusive
licence to sell Lojuxta(R) (lomitapide) across the European
Economic Area, Middle East and North Africa, Switzerland, Turkey,
Israel, Russia, the Commonwealth of Independent States and the
non-EU Balkan states.
Amryt's lead development candidate, AP101, is a potential
treatment for Epidermolysis Bullosa ("EB"), a rare and distressing
genetic skin disorder affecting young children and adults for which
there is currently no treatment. It is currently in Phase 3
clinical trials and recently reported positive unblinded interim
efficacy analysis results and is anticipated will be fully enrolled
by end of H2 2019. The European and US market opportunity for EB is
estimated to be in excess of $1 billion.
In March 2018, Amryt in-licenced a pre-clinical gene-therapy
platform technology, AP103, which offers a potential treatment for
patients with Recessive Dystrophic Epidermolysis Bullosa, a subset
of EB, and is also potentially relevant to other genetic
disorders.
In May 2019, Amryt announced the planned acquisition of Aegerion
Pharmaceuticals. This Transaction will put Amryt on the path to
creating a rare and orphan disease company with a diversified
offering of multiple commercial and development stage assets and
will provide it with scale to support further growth. The
Transaction will give Amryt an expanded commercial footprint to
market two US and EU approved products, lomitapide (Juxtapid(R)
(US/ROW) / Lojuxta(R) (EU)) and metreleptin (Myalept(R) (US) /
Myalepta(R) (EU)). Amryt's leadership team already has a deep
knowledge of both these products and since December 2016 has
successfully commercialized Lojuxta(R) across Europe and the Middle
East.
For more information on Amryt, please visit
www.amrytpharma.com.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
RAGEAEXEFAENEFF
(END) Dow Jones Newswires
July 10, 2019 06:23 ET (10:23 GMT)
Amryt Pharma (LSE:AMYT)
Historical Stock Chart
Von Apr 2024 bis Mai 2024
Amryt Pharma (LSE:AMYT)
Historical Stock Chart
Von Mai 2023 bis Mai 2024